PDB16 A POPULATION-ADJUSTED INDIRECT COMPARISON OF CARDIOVASCULAR BENEFITS BETWEEN ONCE-WEEKLY SEMAGLUTIDE AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES AND HIGH CARDIOVASCULAR RISK